Business Daily Media

The Times Real Estate

.

Connext Successfully Administers First Dose of CNT201 for Dupuytren's Contracture

  • Written by PR Newswire

World's First Genetically Recombinant Collagenase Therapeutics (CNT201) Begins Clinical Trials in Australia

SEOUL, South Korea, July 30, 2024 /PRNewswire/ -- Connext has announced the successful first administration of CNT201, its therapeutic treatment for Dupuytren's contracture, in patients.

Dupuytren's contracture is a debilitating condition characterized by the fibrosis of the fascia between the skin and tendons of the palm due to collagen buildup, causing fingers to become permanently bent and significantly impairing patients' quality of life. Currently, there is no fundamental cure for this condition. Treatments primarily involve surgical interventions like fasciectomy to alleviate symptoms, although non-surgical methods, such as localized injections of collagenase, have shown high patient satisfaction.

It has received IND approval for Phase 1/2 clinical trials from the U.S. FDA and recently completed the Clinical Trial Notification (CTN) process in Australia. The ongoing clinical trial in Australia represents the Phase 1 part of the Phase 1/2 trial, conducted across three hospitals. The trial involves single administrations of four escalating dose levels in patients with Dupuytren's contracture, followed by a four-week evaluation period to assess safety, tolerability, efficacy, pharmacokinetics, and immunogenicity. Connext plans to secure proof-of-concept (PoC) data by mid-next year and determine the optimal dose for Phase 2, with the aim to commence the Phase 2 trial in the latter half of the year.

Connext CEO Woojong Lee remarked, "This first administration marks a significant milestone, offering new hope to patients suffering from Dupuytren's contracture. We are dedicated to developing a safer and more effective treatment to improve their quality of life."

Connext successfully raised a Series B investment at the end of last year and was selected for the Scale-Up TIPS program, enabling the initiation of global clinical trials for Dupuytren's contracture. The company is simultaneously advancing the development of additional indications, including Peyronie's disease and cellulite.

Media Contact:Sangho Lee(Communication)+82-10-8829-4694Sangho.lee@connext.co.kr[1]

References

  1. ^ Sangho.lee@connext.co.kr (www.prnasia.com)

Read more https://www.prnasia.com/story/archive/4471232_AE71232_0

UBH Group Pioneers Australia's Path to Nuclear Sovereignty

Sovereign technology company, UBH Group, has achieved a landmark milestone as the first organisation in the Southern Hemisphere to secure ISO 1944...

The unsung heroes: How MSPs can safeguard SMBs while boosting profitability

In Australia, small-to-medium-sized businesses (SMBs) form the backbone of the economy, accounting for 95% of all businesses. Yet, they remain pri...

Businesses grapple with wage compliance as new laws take effect

Australian businesses are navigating a landscape of rising compliance complexity as new wage theft laws under The Closing Loopholes Acts take hold...

Aerologix Partners with Soar to Create World’s Largest Digital Atlas

Australian drone technology pioneer Aerologix today announced a strategic partnership with digital mapping platform Soar to create what is set to ...

Five signs that AI is growing faster than the internet did

What do Aussie businesses need to do to keep up? There has been mounting chatter that AI is growing even faster than the rapid acceleration we sa...

Protecting Your Small Business from Cyber Threats This Holiday Season

The holiday season brings a surge of online activity for small and medium businesses (SMBs), with increased sales and customer inquiries offering ...

Sell by LayBy